Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -63.74% is 105% below its 5-year average of -31.10%, near the low end of its 5-year range (-63.74%–-10.91%).
89.28% below its 12-month average of -33.67%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-05-31): -16.72%.
RETURN ON ASSETS (ROA)
-63.74%
RETURN ON ASSETS (ROA) AVG TTM
-33.67%
RETURN ON ASSETS (ROA) AVG 3Y
-37.78%
RETURN ON ASSETS (ROA) AVG 5Y
-31.10%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-89.28%
CURRENT VS 3Y AVG
-68.72%
CURRENT VS 5Y AVG
-104.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-107.62%
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.37B
Return on Assets (ROA)
-63.74%
TTM Avg
-33.67%
3Y Avg
-37.78%
5Y Avg
-31.10%
Market Cap
$2.36B
Return on Assets (ROA)
26.56%
TTM Avg
-38.82%
3Y Avg
-43.93%
5Y Avg
-45.44%
Market Cap
$2.39B
Return on Assets (ROA)
24.69%
TTM Avg
32.00%
3Y Avg
9.13%
5Y Avg
-4.32%
Market Cap
$2.40B
Return on Assets (ROA)
-2.55%
TTM Avg
-11.61%
3Y Avg
-25.65%
5Y Avg
-35.91%
Market Cap
$2.41B
Return on Assets (ROA)
-21.30%
TTM Avg
-10.65%
3Y Avg
-10.65%
5Y Avg
-10.65%
Market Cap
$2.42B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$2.31B
Return on Assets (ROA)
13.20%
TTM Avg
13.52%
3Y Avg
17.46%
5Y Avg
11.53%
Market Cap
$2.29B
Return on Assets (ROA)
-12.82%
TTM Avg
-15.67%
3Y Avg
-7.42%
5Y Avg
-2.36%
Market Cap
$2.46B
Return on Assets (ROA)
-33.45%
TTM Avg
-24.16%
3Y Avg
-23.12%
5Y Avg
-103.71%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.37B | -63.74% | -33.67% | -37.78% | -31.10% |
| Liquidia Corporation (LQDA)vs › | $2.36B | 26.56% | -38.82% | -43.93% | -45.44% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 24.69% | 32.00% | 9.13% | -4.32% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -2.55% | -11.61% | -25.65% | -35.91% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.41B | -21.30% | -10.65% | -10.65% | -10.65% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | -42.79% | -37.88% | -40.02% | -36.63% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 13.20% | 13.52% | 17.46% | 11.53% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.29B | -12.82% | -15.67% | -7.42% | -2.36% |
| Disc Medicine, Inc. (IRON)vs › | $2.46B | -33.45% | -24.16% | -23.12% | -103.71% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 0.00% | 1.47% | 1.04% | -2.29% |
ROA
-63.7%
ROE
-84.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-11-30 | -38.43% |
| 2024-11-30 | -28.92% |
| 2023-11-30 | -40.48% |
| 2022-11-30 | -43.28% |
| 2021-11-30 | -24.58% |
| 2020-11-30 | -10.91% |
| 2019-11-30 | -49.26% |
| 2018-11-30 | -20.77% |
